A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy
An Open-Label, Non-randomized, Multi-Center Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand Drug Conjugate MVB-101 Injected Into the Prostate of Patients With Localized Cancer of the Prostate Who Are Scheduled for Prostatectomy
This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose levels of 1, 2, 4, and 8 mg and determine the maximum tolerated dose and recommended Phase 2 dose. Part B will use a Simon two-stage dose-expansion design at one or more selected dose levels to further characterize safety and preliminary efficacy. Participants will undergo safety, pharmacokinetic, multiparametric magnetic resonance imaging, pathological, prostate-specific antigen, and patient-reported outcome assessments.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen (PSMA) and folate receptor alpha (FR-alpha) and carrying monomethyl auristatin E (MMAE). MVB-101 will be administered by direct injection into the prostate under transrectal ultrasound guidance, at a fixed total injection volume of 10 mL (5 mL per lobe), once per week for 4 weeks.
Part A will enroll up to 30 participants. Planned dose levels are 1, 2, 4, and 8 mg per dose. The dose-limiting toxicity evaluation period is Day 1 through Day 29. Accelerated titration rules will be applied to the first two dose levels, and an i3+3 design will guide dose selection. Higher, lower, or intermediate dose levels may be added based on emerging data and Safety Monitoring Committee recommendations. The recommended Phase 2 dose may be the same as or lower than the maximum tolerated dose.
Part B will enroll up to 29 participants per dose group at one or more selected dose levels and will use a Simon two-stage design to better estimate the recommended Phase 2 dose and further characterize safety and preliminary efficacy.
The study includes screening, treatment, safety follow-up approximately 28 days after the last dose, post-treatment multiparametric MRI and PSA assessment, and planned radical prostatectomy at approximately Day 90 (12 weeks). If radical prostatectomy is not performed, a post-treatment prostate biopsy will be obtained as close as possible to the planned prostatectomy date. End of study occurs after completion of safety follow-up, post-treatment MRI and PSA assessment, and prostatectomy or post-treatment biopsy.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Aimee Murphy
- 電話番号:925-818-4403
- メール:amurphy@mvbiotx.com
研究場所
-
-
Alabama
-
Homewood、Alabama、アメリカ、35209
- 募集
- Urology Centers of Alabama
-
コンタクト:
- Meredith Sharpton, PA-C
- 電話番号:205-445-0129
- メール:msharpton@urologyal.com
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- 募集
- Urology San Antonio
-
コンタクト:
- Manuel Hernandez
- 電話番号:210-617-4116
- メール:Manuel.hernandez@usa-clinicaltrials.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed informed consent form.
- Understands the obligation and is capable of attending all follow-up visits.
- Documented, previously untreated, localized adenocarcinoma of the prostate confirmed by multiparametric MRI and prostate biopsy within 3 months before the first dose.
- Scheduled for radical prostatectomy approximately 12 weeks after the first dose of MVB-101.
- Gleason Grade Group 1 with at least one high-risk feature, or Grade Group 2, 3, or 4. High-risk features for Grade Group 1 are PSA density >0.2 ng/mL/cc, PI-RADS 4 or 5, lesion >1.0 cm, lesion volume >0.4 cc, or risk of extraprostatic extension evidenced by capsular abutment or bulge.
- Prostate-specific antigen 20 ng/mL or less.
- Eastern Cooperative Oncology Group performance status 0 or 1.
- Adequate bone marrow and organ function.
- Sexually active participants agree to use barrier protection during treatment and for 1 month after the last MVB-101 dose.
Exclusion Criteria:
- Any prior treatment for prostate cancer, except prior active surveillance is permitted.
- More than 10 mg/day of systemic steroids within 28 days before signing informed consent.
- Prior exposure to auristatin, an auristatin derivative, or a similar molecule.
- Prior or concurrent malignancy whose natural history or treatment could interfere with or affect MVB-101 safety or efficacy assessments.
- Prostatic calcifications.
- Inability to undergo MRI scanning for any reason, including claustrophobia or implanted devices.
- Major surgery within 4 weeks before first dose or planned during the study, other than prostatectomy.
- Toxicity attributed to prior anticancer therapy, other than alopecia and fatigue, not resolved to Grade 1 or baseline before first dose.
- Poorly controlled concurrent disease, including diabetes or hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
- Within 12 months before enrollment: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, or NYHA class III or IV congestive heart failure.
- History of clinically significant lung disease, including interstitial pneumonia, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis, or suspected disease on screening imaging.
- Active bleeding disorder or other history of Grade 3 or higher hemorrhage within 4 weeks before first dose.
- Need for oral vitamin K antagonist anticoagulant therapy. Low-dose anticoagulants to maintain central venous access patency or prevent deep venous thrombosis and therapeutic low-molecular-weight heparin are permitted.
- Deep vein thrombosis or pulmonary embolism within 6 months before first dose.
- Active infection requiring intravenous antibiotics within 1 week before first dose.
- Uncontrolled HIV, known AIDS, chronic hepatitis B, occult hepatitis B, or hepatitis C.
- Current or anticipated need for a strong CYP3A4 inhibitor or inducer. Prior use requires a washout of 21 days or 5 half-lives, whichever is longer, before first dose.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Part A: MVB-101 1 mg
MVB-101 1 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
実験的:Part A: MVB-101 2 mg
MVB-101 2 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
実験的:Part A: MVB-101 4 mg
MVB-101 4 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
実験的:Part A: MVB-101 8 mg
MVB-101 8 mg by intraprostatic injection once weekly for 4 weeks. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
|
実験的:Part B: MVB-101 Dose Expansion
MVB-101 at one or more selected dose levels by intraprostatic injection once weekly for 4 weeks. Other schedules may also be explored. |
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment-emergent adverse events
時間枠:From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)
|
Number and percentage of participants with treatment-emergent adverse events, treatment-related adverse events, serious adverse events, and clinically significant changes in vital signs, physical examinations, electrocardiogram (ECG) and clinical laboratory tests, graded using NCI CTCAE version 6.0. |
From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)
|
|
Dose-limiting toxicities
時間枠:Day 1 through Day 29
|
Number and percentage of participants with a dose-limiting toxicity, assessed according to protocol-defined criteria using NCI CTCAE version 6.0. |
Day 1 through Day 29
|
|
Maximum tolerated dose
時間枠:Through completion of Part A dose escalation, up to 12 months
|
Maximum tolerated dose of intraprostatic MVB-101 determined from dose-limiting toxicities and cumulative safety data under the i3+3 design. |
Through completion of Part A dose escalation, up to 12 months
|
|
Recommended Phase 2 dose
時間枠:Through completion of dose escalation and applicable dose-expansion, up to 18 months
|
Recommended Phase 2 dose of intraprostatic MVB-101 based on safety, tolerability, pharmacokinetics, and available efficacy data. |
Through completion of dose escalation and applicable dose-expansion, up to 18 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacokinetic parameters of MVB-101 and MMAE
時間枠:Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose
|
Plasma concentration-time analysis will be performed using PK concentration values over time. |
Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose
|
|
Pathological response in excised prostate tissue
時間枠:At prostatectomy or post-treatment biopsy, approximately Day 90
|
Number and percentage of participants with persistence or absence of the dominant index prostate cancer lesion or any lesion on pathological examination of prostatectomy tissue; post-treatment multicore biopsy is used if planned prostatectomy is not performed. |
At prostatectomy or post-treatment biopsy, approximately Day 90
|
|
Radiologic response by multiparametric MRI
時間枠:Baseline and approximately 10 days, but no more than 14 days, before prostatectomy
|
Number and percentage of participants with persistence or absence of baseline prostate cancer lesions on post-treatment multiparametric MRI. |
Baseline and approximately 10 days, but no more than 14 days, before prostatectomy
|
|
International Prostate Symptom Score
時間枠:Baseline through safety follow-up (approximately Day 50)
|
Observed values and change from baseline in International Prostate Symptom Score (IPSS). IPSS score values between 0-5 with lower scores indicating better performance/ improvement. |
Baseline through safety follow-up (approximately Day 50)
|
|
International Index of Erectile Function-5
時間枠:Baseline through safety follow-up (approximately Day 50)
|
Observed values and change from baseline in International Index of Erectile Function-5 (IIEF-5). IIEF-5 is scored with values 1-5 with higher scores indicating better performance/ improvement. |
Baseline through safety follow-up (approximately Day 50)
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Stephen Snowdy, PhD、MultiValent Biotherapies, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- MVB-101-101
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。